A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

May 31, 2008

Conditions
Hypertension
Interventions
DRUG

PS433540

200mg capsule, once daily for 28 days

DRUG

placebo

placebo capsule, once daily for 28 days

DRUG

PS433540

500mg capsule, once daily for 28 days

Trial Locations (15)

20745

MD Medical Research, Oxon Hill

32720

University Clinical Research Deland, LLC, DeLand

33308

Alan Graff, MD PA, Fort Lauderdale

45219

Lindner Clinical Trial Center, Cincinnati

53719

Gemini Scientific, Madison

60467

Orland Primary Care Specialists, Orland Park

60607

Cedar Crosse Research Center, Chicago

75006

Punzi Medical Center, Carrolton

85282

Premiere Pharmaceutical Research, LLC, Tempe

90057

National Research Institute, Los Angeles

90806

Long Beach Center for Clinical Research, Long Beach

91361

Westlake Medical Center, Westlake Village

92780

Orange County Research Center, Tustin

95648

Clinical Trials Research, Lincoln

95825

Sacramento Research Medical Group, Sacramento

Sponsors
All Listed Sponsors
lead

Ligand Pharmaceuticals

INDUSTRY

NCT00522925 - A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension | Biotech Hunter | Biotech Hunter